Glaukos stock gains institutional support as Bank of America builds position

Published on 09/20/2026 at 20:26 | Editorial responsibility: Rafael Müller, Editor-in-Chief AD HOC NEWS

Glaukos stock drew attention as Bank of America Corp DE disclosed a new 587,327-share stake valued at about USD 82.1 million in the second quarter, per a filing dated September 20, 2026. The shares last closed at USD 161.56 on September 18, 2026, near the upper end of their 52-week range.

GKOS, US3773221029, Illustration mit AI erstellt.

Glaukos Corporation stock (ISIN US3773221029) attracted fresh institutional interest after Bank of America Corp DE disclosed a new position of 587,327 shares in the second quarter of 2026, valued at approximately USD 82.1 million and representing about 1.00 percent of the company as of the latest filing, according to MarketBeat on September 20, 2026.

Glaukos stock trades near the top of its 52-week range

For investors, the current valuation context is important: recent data show Glaukos stock last traded at USD 161.56 on its primary listing, with the quote dated September 18, 2026, and a 52-week range between USD 73.60 and USD 190.46, per figures reported by Reuters.

The current level near USD 161.56 therefore sits more than double the 52-week low of USD 73.60 and moderately below the 52-week high of USD 190.46, a quantified span that highlights how strongly the shares have appreciated over the past year while still leaving room below their peak. This range gives retail investors a concrete sense of where the stock trades within its recent history and frames the institutional buying in a high-price environment.

Latest quarterly figures show rapid revenue growth and continued losses

Beyond the share price, recent fundamentals help explain why large institutions are engaging with Glaukos. The company most recently reported quarterly results for the second quarter of 2026, with the release dated July 29, 2026 and covering that quarter, according to MarketBeat.

In that second quarter of 2026, Glaukos generated revenue of USD 185.61 million, beating analyst expectations of USD 150.93 million and marking a 49.6 percent increase compared with the same quarter a year earlier, according to the same MarketBeat overview.

On the earnings side, Glaukos reported a loss of USD 0.14 per share for that quarter, which nevertheless came in USD 0.07 better than the consensus forecast of a USD 0.21 loss per share, as summarized by MarketBeat.

Despite this earnings beat, the company still posted a negative net margin of 30.68 percent and a negative return on equity of 6.37 percent for the period, underscoring that Glaukos remains in an investment and scaling phase rather than mature profitability, according to figures cited by MarketBeat.

Analyst consensus and institutional flows shape the narrative

MarketBeat also reports that based on its compiled data, Glaukos currently carries an average analyst rating of Moderate Buy, with a consensus price target of USD 178.08 as of September 20, 2026, indicating that covering analysts see modest upside from the recent close while remaining generally positive on the stock, according to MarketBeat.

With the share price around USD 161.56 as of September 18, 2026 and the consensus target at USD 178.08, the implied difference of roughly USD 16.52 per share represents single-digit percent potential upside from current levels, positioning Glaukos as a stock where analysts expect further gains but not a dramatic re-rating in the immediate term.

The newly disclosed Bank of America Corp DE stake sits alongside moves by other institutional investors that have adjusted their positions over recent quarters, though the detailed figures for those other institutions are less central than Bank of America Corp DE's approximately USD 82.1 million allocation, which stands out as a sizeable vote of confidence in the company’s trajectory, as highlighted by MarketBeat.

Stock level and investor takeaway

As of the most recent completed trading day, September 18, 2026, Glaukos stock closed at USD 161.56 on its primary exchange, trading within a 52-week band between USD 73.60 and USD 190.46, figures that frame both the strong appreciation already seen and the gap to the prior high. In this setting, the combination of nearly 50 percent year-over-year revenue growth, an earnings loss that is narrower than expected, and fresh institutional buying from Bank of America Corp DE offers investors a concise picture of a growth-focused medical instruments company that continues to attract capital at elevated share levels.